Antithrombotic treatment switching in elderly patients with atrial fibrillation and the risk of thromboembolism, bleeding, and cardiac death.

ABSTRACT:

Background

Risks of antithrombotic switching is not investigated in elderly atrial fibrillation patients.

Objectives

To investigate the effectiveness and safety of antithrombotic treatment and switching of antithrombotic treatment in elderly patients (aged 75 years or older) with atrial fibrillation (AF).

Methods

We conducted a cohort study of 2943 patients with AF (Carrebean-elderly), hospitalized during 2010-2017. Cox models were used to estimate the association of antithrombotic treatment (warfarin, direct oral anticoagulants [DOAC] and non-guideline-recommended therapy [NG], i.e., aspirin and low-molecular-weight heparin) at discharge and antithrombotic treatment switching during follow-up with the risk of a composite and single end points of thromboembolism, blee

SUBMITTER: Ehrlinder H 

PROVIDER: S-EPMC9596606 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature